IL281450A - Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor - Google Patents

Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Info

Publication number
IL281450A
IL281450A IL281450A IL28145021A IL281450A IL 281450 A IL281450 A IL 281450A IL 281450 A IL281450 A IL 281450A IL 28145021 A IL28145021 A IL 28145021A IL 281450 A IL281450 A IL 281450A
Authority
IL
Israel
Prior art keywords
pai
inhibitors
plasminogen activator
activator inhibitor
inhibitor
Prior art date
Application number
IL281450A
Other languages
English (en)
Hebrew (he)
Original Assignee
Eirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirion Therapeutics Inc filed Critical Eirion Therapeutics Inc
Publication of IL281450A publication Critical patent/IL281450A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Biophysics (AREA)
IL281450A 2018-09-13 2021-03-11 Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor IL281450A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731074P 2018-09-13 2018-09-13
PCT/US2019/050849 WO2020056160A1 (en) 2018-09-13 2019-09-12 Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Publications (1)

Publication Number Publication Date
IL281450A true IL281450A (en) 2021-04-29

Family

ID=68052024

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281450A IL281450A (en) 2018-09-13 2021-03-11 Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Country Status (12)

Country Link
US (1) US20220105068A1 (https=)
EP (1) EP3849539A1 (https=)
JP (2) JP2021535925A (https=)
KR (2) KR102884331B1 (https=)
CN (2) CN113056268A (https=)
AU (1) AU2019338459B2 (https=)
BR (1) BR112021004542A2 (https=)
CA (1) CA3112558A1 (https=)
IL (1) IL281450A (https=)
MX (2) MX2021002995A (https=)
SG (1) SG11202102478SA (https=)
WO (1) WO2020056160A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
CN113155987B (zh) * 2020-12-28 2023-06-06 浙江工商大学 一种微针贴片及其制备方法、应用
AU2024344613A1 (en) 2023-09-18 2026-04-23 Eirion Therapeutics, Inc. Topical compositions and uses of pai-1 inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
WO2001051085A1 (en) * 2000-01-14 2001-07-19 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
WO2003071267A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
EP1509236A4 (en) * 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
WO2006018024A2 (en) * 2004-08-18 2006-02-23 Ace Aps Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
EP2015773A4 (en) 2006-04-27 2010-05-05 Anterios Inc EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
WO2009123241A1 (ja) * 2008-03-31 2009-10-08 株式会社レナサイエンス プラスミノーゲンアクチベーターインヒビター-1阻害剤
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
US20120114745A1 (en) * 2009-06-26 2012-05-10 Nam-Mew Pui Method for treating or ameliorating mucocutaneous or ocular toxicities
EP2667854B1 (en) 2011-01-24 2019-01-16 Anterios, Inc. Nanoparticle compositions
KR20140005998A (ko) 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
WO2013096026A1 (en) 2011-12-21 2013-06-27 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same

Also Published As

Publication number Publication date
BR112021004542A2 (pt) 2021-06-08
CN113056268A (zh) 2021-06-29
KR20210057141A (ko) 2021-05-20
MX2021002995A (es) 2021-07-15
CN120983628A (zh) 2025-11-21
WO2020056160A1 (en) 2020-03-19
KR102884331B1 (ko) 2025-11-13
JP2025011085A (ja) 2025-01-23
AU2019338459B2 (en) 2025-07-10
CA3112558A1 (en) 2020-03-19
KR20250163416A (ko) 2025-11-20
MX2025004193A (es) 2025-05-02
JP2021535925A (ja) 2021-12-23
EP3849539A1 (en) 2021-07-21
SG11202102478SA (en) 2021-04-29
AU2019338459A1 (en) 2021-04-08
US20220105068A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
DK4031547T3 (da) Plasmakallikreininhibitorer og anvendelser deraf
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
IL288381A (en) Tead inhibitors and their uses
IL288384A (en) Tead inhibitors and their uses
EP3805217A4 (en) ERK INHIBITOR AND ITS USE
IL289612A (en) Hpk1 inhibitors and uses thereof
EP3746071A4 (en) GCN2 INHIBITORS AND THEIR USES
EP3867253A4 (en) Indole ahr inhibitors and uses thereof
EP3880677A4 (en) Erk inhibitors and uses thereof
IL284799A (en) Tyk2 inhibitors and uses thereof
IL286248A (en) Tyk2 inhibitors and uses thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
EP3866927A4 (en) Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
IL287768A (en) Kcnt1 inhibitors and methods of use
IL268981A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
IL291217A (en) Usp30 inhibitors and uses thereof
DK3470409T3 (da) Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer
IL281450A (en) Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
IL280770A (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
IL286622A (en) Prmt5 inhibitors and uses thereof
IL281451A (en) Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
IL276324A (en) 4-Hydroxypiperidine derivatives and their use as ubiquitin-specific protease 19 (USP19) inhibitors
EP4192836A4 (en) ATR INHIBITORS AND THEIR USES
EP4017857A4 (en) METTL 16 INHIBITORS AND THEIR USES